{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:57:59Z","timestamp":1784084279889,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Pseudomonas aeruginosa is a clinically important opportunistic pathogen in dogs and cats, frequently associated with chronic infections and increasing antimicrobial resistance. In 2024, 111 P. aeruginosa isolates from 77 dogs and 34 cats were analyzed. Isolates originated from the external ear canal of animals with chronic otitis externa (66\/111, 59.5%) and the nasal cavity of animals with chronic rhinitis (29\/111, 26.1%), wounds (7\/111, 6.3%), the conjunctival sac (5\/111, 4.5%), and the skin (4\/111, 3.6%). MICs for ciprofloxacin, meropenem, ceftazidime, aztreonam, piperacillin, piperacillin\/tazobactam, and colistin were determined using a commercial microdilution panel and interpreted with CLSI M100 breakpoints for P. aeruginosa. Susceptibility was highest to piperacillin and piperacillin\/tazobactam (both 90.1% susceptible and 7.2% resistant). Resistance was more frequent to ciprofloxacin (26.1%), meropenem (17.1%), and ceftazidime (16.2%). Colistin resistance (MIC \u2265 4 \u00b5g\/mL) was detected in 6.3% of isolates. MDR (Magiorakos definition; non-susceptibility to \u22651 agent in \u22653 antimicrobial categories) was identified in 17\/111 (15.3%) isolates. Meropenem non-susceptibility was strongly associated with ceftazidime non-susceptibility (25\/111, 22.5%; OR 11.21; 95% CI 4.29\u201329.30; phi 0.51; p = 2.4 \u00d7 10\u22127). These findings provide baseline phenotypic surveillance data for P. aeruginosa from companion animals in Poland and highlight clinically relevant co-non-susceptibility patterns involving meropenem and ceftazidime.<\/jats:p>","DOI":"10.3390\/microorganisms14020374","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:35:37Z","timestamp":1770287737000},"page":"374","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MIC Distributions and CLSI-Categorized Resistance in Pseudomonas aeruginosa from Companion Animals in Poland: Evidence of Strong Meropenem\u2013Ceftazidime Co-Non-Susceptibility"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-0810","authenticated-orcid":false,"given":"Dawid","family":"Ja\u0144czak","sequence":"first","affiliation":[{"name":"Department of Infectious and Invasive Diseases and Veterinary Administration, Institute of Veterinary Medicine, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Lwowska 1, 87-100 Toru\u0144, Poland"},{"name":"Animallab Veterinary Laboratory in Warsaw, \u015arodkowa 2\/4, 03-430 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"G\u00f3recki","sequence":"additional","affiliation":[{"name":"Animallab Veterinary Laboratory in Warsaw, \u015arodkowa 2\/4, 03-430 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"W\u00f3jtowicz","sequence":"additional","affiliation":[{"name":"Animallab Veterinary Laboratory in \u0141\u00f3d\u017a, Ignacego Paderewskiego 6, 93-509 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Szalu\u015b-Jordanow","sequence":"additional","affiliation":[{"name":"Department of Small Animal Diseases with Clinic, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Nowoursynowska 159c, 02-776 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Moradali, M.F., Ghods, S., and Rehm, B.H.A. (2017). Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Front. Cell. Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00039"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic Resistance in Pseudomonas aeruginosa: Mechanisms and Alternative Therapeutic Strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"#cr-split#-ref_3.1","unstructured":"EFSA Panel on Animal Health and Welfare (AHAW) (2022). Assessment of Listing and Categorisation of Animal Diseases within the Framework of the Animal Health Law (Regulation"},{"key":"#cr-split#-ref_3.2","unstructured":"(EU) No 2016\/429): Antimicrobial-Resistant Pseudomonas aeruginosa in Dogs and Cats. EFSA J., 20, e07310."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Secker, B., Shaw, S., and Atterbury, R.J. (2023). Pseudomonas spp. in Canine Otitis Externa. Microorganisms, 11.","DOI":"10.3390\/microorganisms11112650"},{"key":"ref_5","first-page":"1231","article-title":"Pseudomonas Otitis Externa in Dogs","volume":"59","author":"Pye","year":"2018","journal-title":"Can. Vet. J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yin, R., Cheng, J., Wang, J., Li, P., and Lin, J. (2022). Treatment of Pseudomonas aeruginosa Infectious Biofilms: Challenges and Strategies. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.955286"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/vcp.12749","article-title":"Mucoid Pseudomonas aeruginosa Infection in a Cat with Severe Chronic Rhinosinusitis","volume":"48","author":"Sharma","year":"2019","journal-title":"Vet. Clin. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jvim.14627","article-title":"Antimicrobial Use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases","volume":"31","author":"Lappin","year":"2017","journal-title":"J. Vet. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tvjl.2019.02.008","article-title":"International Society for Companion Animal Infectious Diseases (ISCAID) Guidelines for the Diagnosis and Management of Bacterial Urinary Tract Infections in Dogs and Cats","volume":"247","author":"Weese","year":"2019","journal-title":"Vet. J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pereira, A.C., de Sousa, T., Silva, C., Igrejas, G., and Poeta, P. (2025). Impact of Antimicrobial Resistance of Pseudomonas aeruginosa in Urine of Small Companion Animals in Global Context: Comprehensive Analysis. Vet. Sci., 12.","DOI":"10.3390\/vetsci12020157"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Scarpellini, R., Giunti, M., Bulgarelli, C., Esposito, E., Mondo, E., Tumietto, F., and Piva, S. (2025). Investigating Bacterial Bloodstream Infections in Dogs and Cats: A 4-Year Surveillance in an Italian Veterinary University Hospital. Vet. Sci., 12.","DOI":"10.20944\/preprints202504.0156.v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/1751-7915.14487","article-title":"Antibiotic Influx and Efflux in Pseudomonas aeruginosa: Regulation and Therapeutic Implications","volume":"17","author":"Wu","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3201\/eid2406.180335","article-title":"Zooanthroponotic Transmission of Drug-Resistant Pseudomonas aeruginosa, Brazil","volume":"24","author":"Fernandes","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Secker, B., Shaw, S., Hobley, L., and Atterbury, R.J. (2025). Genomic and Phenotypic Characterisation of Pseudomonas aeruginosa Isolates from Canine Otitis Externa Reveals High-Risk Sequence Types Identical to Those Found in Human Nosocomial Infections. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1526843"},{"key":"ref_15","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2024). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [34th ed.]. CLSI Supplement M100."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1128\/AAC.40.10.2288","article-title":"Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in Pseudomonas aeruginosa","volume":"40","author":"Kok","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/17425250903145251","article-title":"Ampicillin-Sulbactam: An Update on the Use of Parenteral and Oral Forms in Bacterial Infections","volume":"5","author":"Betrosian","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Elfadadny, A., Uchiyama, J., Goto, K., Imanishi, I., Ragab, R.F., Nageeb, W.M., Iyori, K., Toyoda, Y., Tsukui, T., and Ide, K. (2023). Antimicrobial Resistance and Genotyping of Pseudomonas aeruginosa Isolated from Canine Otitis Externa. Front. Vet. Sci., 10.","DOI":"10.3389\/fvets.2023.1074127"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"de Sousa, T., Garc\u00eas, A., Silva, A., Lopes, R., Alegria, N., H\u00e9braud, M., Igrejas, G., and Poeta, P. (2023). The Impact of the Virulence of Pseudomonas aeruginosa Isolated from Dogs. Vet. Sci., 10.","DOI":"10.3390\/vetsci10050343"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rosales, R.S., Ram\u00edrez, A.S., Moya-Gil, E., de la Fuente, S.N., Su\u00e1rez-P\u00e9rez, A., and Poveda, J.B. (2024). Microbiological Survey and Evaluation of Antimicrobial Susceptibility and MDR Phenotypes in Canine Otitis Externa Submissions. Animals, 14.","DOI":"10.3390\/ani14050742"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Meepoo, W., Jaroensong, T., Pruksakorn, C., and Rattanasrisomporn, J. (2022). Investigation of Bacterial Isolations and Antimicrobial Susceptibility of Chronic Rhinitis in Cats. Animals, 12.","DOI":"10.3390\/ani12121572"},{"key":"ref_23","unstructured":"European Medicines Agency (EMA), and Antimicrobial Advice ad hoc Expert Group (AMEG) (2019). Answer to the Request from the European Commission for Updating the Scientific Advice on the Impact on Public Health and Animal Health of the Use of Antibiotics in Animals\u2014Categorisation of Antimicrobials, European Medicines Agency. EMA\/CVMP\/CHMP\/682198\/2017."},{"key":"ref_24","unstructured":"European Commission (2022). Commission Implementing Regulation (EU) 2022\/1255 of 19 July 2022 Designating Antimicrobials or Groups of Antimicrobials Reserved for Treatment of Certain Infections in Humans, in Accordance with Regulation (EU) 2019\/6 (Text with EEA Relevance). Off. J. Eur. Union, 50, 58\u201360."},{"key":"ref_25","unstructured":"World Health Organization (2024). WHO List of Medically Important Antimicrobials\u2014A Risk Management Tool for Mitigating Antimicrobial Resistance Due to Non-Human Use, World Health Organization."},{"key":"ref_26","unstructured":"European Commission (2026, February 02). Commission Implementing Regulation (EU) 2024\/1973 of 18 July 2024 Establishing a List of Antimicrobials Which Shall Not Be Used in Accordance with Articles 112 and 113 of Regulation (EU) 2019\/6 of the European Parliament and of the Council or Which Shall Only Be Used in Accordance with Those Articles Subject to Certain Conditions (Text with EEA Relevance). Off. J. Eur. Union 2024, L, 2024\/1973, 1\u20139. ELI. Available online: http:\/\/data.europa.eu\/eli\/reg_impl\/2024\/1973\/oj."},{"key":"ref_27","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2025). Surveillance of Antimicrobial Resistance in Europe, 2024 Data, ECDC."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12953-023-00217-6","article-title":"Proteomic Analysis of Ceftazidime- and Meropenem-Exposed Pseudomonas aeruginosa ATCC 9027","volume":"21","author":"Ngo","year":"2023","journal-title":"Proteome Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e03896-24","DOI":"10.1128\/mbio.03896-24","article-title":"Multi-Omics Profiling of Cross-Resistance between Ceftazidime-Avibactam and Meropenem Identifies Common and Strain-Specific Mechanisms in Pseudomonas aeruginosa Clinical Isolates","volume":"16","author":"Bartmanski","year":"2025","journal-title":"mBio"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cvsm.2014.11.005","article-title":"Antimicrobial Stewardship in Small Animal Veterinary Practice: From Theory to Practice","volume":"45","author":"Guardabassi","year":"2015","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/2\/374\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:51:24Z","timestamp":1770288684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/2\/374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["microorganisms14020374"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14020374","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}